Reference no: EM133860579
Assignment:
Although there were significant increases over the decade in the percentage of studies that checked adherence to treatment and used supervision to promote fidelity, the majority (55%) of the studies essentially ignored the issue of treatment fidelity. Furthermore, only one out of eight studies in the most recent period (1986-1988) combined the use of treatment manuals, supervision of treatment agents, and checking of adherence to protocol. Finally, attention given to the aforementioned aspects of fidelity did not differ significantly across journal domains. The overall implication of the review of existing practices is that investigators, reviewers, and journal editors need to give even greater consideration to the issues associated with fidelity. Specific recommendations for improving the promotion and verification of treatment fidelity in outcome studies were offered.
Question 1. How should the body surface area be calculated when giving drugs for which doses are given per square metre of body surface area?
Question 2. Where can I find a reference table that shows drugs that can safely be prescribed and avoided during pregnancy and during lactation? Might this be included in the next edition of Kumar and Clark's Clinical Medicine?
Question 3. Where might I find a reference table showing paediatric drug doses?
Question 4. My question is concerned with the practical use of steroids. In inflammatory bowel disease, what doses are used and when is the dose reduced?
Question 5. What is the safe dosage/length of treatment for the drug dexmethasone so that its destructive effects are avoided?
Question 6. 1. Please explain 'odds ratio' and 'risk ratio'.
2. What is meant by saying that diabetics have a 3.3 risk ratio of developing dementia?
Question 7. I'm a medical student from the Faculty of Medicine, Peradeniya, Sri Lanka. I have a question about the management of aspirin poisoning. Is it reasonable to carry out a postalkaline diuresis in these patients?
Question 8. What is meant by intermediate syndrome in organophosphorus poisoning?
Question 9. What are the pulmonary manifestations of Pink's disease and how common are they relative to the usual cerebral, skin and renal effects?
Question 10. Is it necessary to administer antivenom to a person bitten by a snake 6 hours previously, presenting only with local leg swelling over the bitten site and so far no other systemic feature of poisoning?